EUCTR2012-005078-70-DK进行中（未招募）1 期
Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) A randomized, multidisciplinary, multinational AIO/DGAV/DGVS phase III trial.
niversity Medical Center Hamburg-Eppendorf0 个研究点目标入组 60 人开始时间: 2015年9月2日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Eligibility criteria for treatment phase (before randomization)
- •1. Histologically confirmed adenocarcinoma of biliary tract (intrahepatic, hilar or extrahepatic cholangiocarcinoma or muscle invasive gallbladder carcinoma) after radical surgical therapy with macroscopically complete resection (mixed tumor entities (HCC/CCA) are excluded)
- •2. Macroscopically complete resection (R0/1) within 6 (-16) weeks before scheduled start of chemotherapy
- •3. ECOG 0-1
- •4. Age >18 years
- •5. Adequate hematologic function: ANC = 1.5 x 10^9/L, platelets = 100 x10^9/L, hemoglobin = 9 g/dl or = 5.59 mmol/L
- •6. Adequate liver function as measured by serum transaminases (AST and ALT) <= 5 x ULN and bilirubin <= 3 x ULN
- •7. Adequate renal function, i.e. serum creatinine <= 1.5 x ULN, glomerular filtration rate = 60 mL/min (MDRD)
- •8. No active uncontrolled infection, except chronic viral hepatitis under antiviral therapy
- •9. No concurrent treatment with other experimental drugs or other anti-cancer therapy, treatment in a clinical trial within 30 days prior to randomization
- •10. Negative serum pregnancy test within 7 days of starting study treatment in pre-menopausal women and women <1 year after the onset of menopause (Note: a negative test has to be reconfirmed by a urine test, should the 7-day window be exceeded)
- •11. Written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 280
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 160
排除标准
- •1. Prior chemotherapy for biliary tract cancer
- •2.Previous malignancy within 3 years or concomitant malignancy, except: non-melanomatous skin cancer or adequately treated in situ cervical cancer
- •3. Severe or uncontrolled cardiovascular disease (congestive heart failure NYHA III or IV, unstable angina pectoris, history of myocardial infarction in the last 3 months, significant arrhythmia)
- •4. Psychiatric disorder precluding understanding of information of trial related topics and giving informed consent
- •5. Serious underlying medical conditions (judged by the investigator), that could impair the ability of the patient to participate in the trial
- •6. Fertile women (< 1 year after last menstruation) and procreative men not willing or unable to use effective means of contraception (oral contraceptives, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly or surgically sterile)
- •7. Pregnant or lactating women
研究者
相似试验
进行中（未招募）
1 期
Prophylactic combined chemotherapy for patients with cholangiocarcinoma after curative intent of carcinoma resection and muscle invasive gallbladder carcinoma.Cholangiocarcinoma and gallbladder carcinomaMedDRA version: 20.0Level: LLTClassification code 10017620Term: Gallbladder carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10008593Term: CholangiocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-005078-70-ATniversity Medical Center Hamburg-Eppendorf440
进行中（未招募）
1 期
Prophylactic combined chemotherapy for patients with cholangiocarcinoma after curative intent of carcinoma resection and muscle invasive gallbladder carcinoma.Cholangiocarcinoma and gallbladder carcinomaMedDRA version: 20.0Level: LLTClassification code 10017620Term: Gallbladder carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10008593Term: CholangiocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-005078-70-ITIVERSITäTKLINIKUM HAMBURG-EPPENDORF781
招募中
3 期
Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial)Biliary tract cancerCholangio/gallblader carcinoma10019815NL-OMON53034Amsterdam UMC172
进行中（未招募）
1 期
Prophylactic combined chemotherapy for patients with cholangiocarcinoma after curative intent of carcinoma resection and muscle invasive gallbladder carcinoma.Cholangiocarcinoma and gallbladder carcinomaMedDRA version: 20.0Level: LLTClassification code 10017620Term: Gallbladder carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10008593Term: CholangiocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-005078-70-DEniversity Medical Center Hamburg-Eppendorf781
进行中（未招募）
1 期
Prophylactic combined chemotherapy for patients with cholangiocarcinoma after curative intent of carcinoma resection and muscle invasive gallbladder carcinoma.Cholangiocarcinoma and gallbladder carcinomaMedDRA version: 20.0Level: LLTClassification code 10017620Term: Gallbladder carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10008593Term: CholangiocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-005078-70-NLniversity Medical Center Hamburg-Eppendorf781